At the time of this publication, a phase 2 open-label study is ongoing for the use of IL-22-Fc for IBD (ClinicalTrials.gov Identifier, NCT03650413) along with an ongoing study of the role of IL-22 in COPD (ClinicalTrials.gov Identifier, NCT02655302). This evidence concerns the gene IL22 and chronic obstructive pulmonary disease.